Related references
Note: Only part of the references are listed.Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)
Jennifer A. Woyach et al.
BLOOD (2014)
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy
Jennifer A. Woyach et al.
BLOOD (2014)
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
Susan O'Brien et al.
LANCET ONCOLOGY (2014)
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity
S. Cheng et al.
LEUKEMIA (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia
Davide Rossi et al.
BLOOD (2013)
Biology of Chronic Lymphocytic Leukemia in Different Microenvironments Clinical and Therapeutic Implications
Yair Herishanu et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2013)
Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies
Adrian Wiestner
JOURNAL OF CLINICAL ONCOLOGY (2013)
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi
Robbert Hoogeboom et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy
S. E. M. Herman et al.
LEUKEMIA (2013)
Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia
S. E. M. Herman et al.
LEUKEMIA (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
Sabine Ponader et al.
BLOOD (2012)
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia
Adrian Wiestner
BLOOD (2012)
Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen
Christoph Steininger et al.
BLOOD (2012)
Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy
Joseph J. Buggy et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2012)
Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling
Marcus Duehren-von Minden et al.
NATURE (2012)
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Yair Herishanu et al.
BLOOD (2011)
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation
Patricia Perez-Galan et al.
BLOOD (2011)
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E. M. Herman et al.
BLOOD (2011)
B-cell receptor signaling in chronic lymphocytic leukemia
Freda K. Stevenson et al.
BLOOD (2011)
Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Philip C. Amrein et al.
CLINICAL CANCER RESEARCH (2011)
Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma
Marc A. Weniger et al.
CLINICAL CANCER RESEARCH (2011)
Syk mediates BCR- and CD40-signaling integration during B cell activation
Haiyan Ying et al.
IMMUNOBIOLOGY (2011)
Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia
Jan A. Burger
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2011)
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Jonathan W. Friedberg et al.
BLOOD (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The role of Toll-like receptors in chronic B cell malignancies
Marta Muzio et al.
LEUKEMIA & LYMPHOMA (2009)
Signalling crosstalk in B cells: managing worth and need
Michael P. Cancro
NATURE REVIEWS IMMUNOLOGY (2009)
The Role of Tec Family Kinases in Mononuclear Phagocytes
Afitap Derya Koepruelue et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2009)
A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies
Anna Lanemo Myhrinder et al.
BLOOD (2008)
Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA
Charles C. Chu et al.
BLOOD (2008)
Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation
P. Ghia et al.
JOURNAL OF INTERNAL MEDICINE (2008)
BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-κB pathway
Tomoyuki Endo et al.
BLOOD (2007)
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase
Zhengying Pan et al.
CHEMMEDCHEM (2007)
In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells
BT Messmer et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Mechanisms of disease: Chronic lymphocytic leukemia
N Chiorazzi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
